Nasdaq dbtx.

BOSTON, March 22, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Nasdaq dbtx. Things To Know About Nasdaq dbtx.

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Dec 11, 2021 · To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ... Fintel reports that on May 12, 2023, HC Wainwright & Co. reiterated coverage of Decibel Therapeutics (NASDAQ:DBTX) with a Buy recommendation. Analyst Price Forecast Suggests 272.02% Upside. As of ...BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Feb 10, 2022 · Decibel Therapeutics Inc (NASDAQ: DBTX) announced the presentation of preclinical data on DB-OTO, its lead gene therapy product candidate. DB-OTO is a dual-vector adeno-associated candidate ...

06-Sept-2023 ... Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)'s sale to Nautic Partners for $10.50 in cash per share. If you are a Tabula Rasa shareholder, click ...

5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ...Decibel Therapeutics, Inc. Common Stock (DBTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...Decibel Therapeutics, Inc. (DBTX) Stock Price | Stock Quote Nasdaq - MarketScreener DECIBEL THERAPEUTICS, INC. Decibel Therapeutics, Inc. Stock price Equities DBTX …

BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

Find the latest Institutional Holdings data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.

Translating rapid advances in hearing science to meet the urgent needs of hundreds of millions worldwide with disabling hearing loss.Find the latest dividend history for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Decibel Therapeutics, Inc. (Nasdaq - DBTX) Under the terms of the Merger Agreement, Decibel will be acquired by Regeneron Pharmaceuticals, Inc. (Nasdaq - REGN). Decibel shareholders will receive ...Feb 12, 2021 · Follow. BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to ... Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ...BOSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss.BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The deal also has an additional contingent payment of $3.50 per share for DBTX stock if certain milestones are met. At the $4 price for DBTX stock, this offer represents a 43.3% premium over its ...BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug …

May 10, 2023 · BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...

(DBTX) reported a total revenue of $12.5 million in the first quarter of 2022 ... NASDAQ · NYSE · Blog. Need Help? [email protected]. Create your mobile categories ...Fintel reports that on May 12, 2023, HC Wainwright & Co. reiterated coverage of Decibel Therapeutics (NASDAQ:DBTX) with a Buy recommendation. Analyst Price Forecast Suggests 272.02% Upside. As of ...09-Aug-2023 ... Decibel Therapeutics (NASDAQ:DBTX) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ:REGN).BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...DBX NASDAQ. DBX NASDAQ. DBX NASDAQ. DBX NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview . News Ideas Financials Technicals Forecast . DBX chart. Today 0.93% 5 days −1.40% 1 month −4.98% 6 months 20.14% Year to date 15.52% 1 year 21.65% 5 years 4.77% All time −9.90%. Key stats.BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering an...DECIBEL THERAPEUTICS, INC. Add to a list PDF Report Decibel Therapeutics, Inc. Stock price Equities DBTX US24343R1068 Biotechnology & Medical Research Summary Charts News Calendar Company Funds and ETFs -40% on all our subscriptions* Enjoy this offer * See conditions on website Chart Decibel Therapeutics, Inc. Duration Period Style Dynamic ChartA company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at March 2023, Decibel Therapeutics had cash of US$88m and no debt ...

Decibel Therapeutics ( NASDAQ: DBTX) is an early-stage gene therapy company focused on developing new medicines for hearing and balance disorders. The company’s biological hypothesis is centered ...

NASDAQ: ALXO. age1. INVISIBLE. The Longevity Fund. INVISIBLE. The Longevity Fund. INVISIBLE. The Longevity Fund. NASDAQ: DBTX.

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Aug 28, 2023 · Decibel Therapeutics, Inc. (Nasdaq: DBTX), relating to its proposed acquisition by Regeneron Pharmaceuticals, Inc. Under the terms of the tender offer, DBTX shareholders will receive $4.00 in cash ... BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...(Nasdaq - SOVO), Computer Task Group, Incorporated (Nasdaq - CTG). Press ... (Nasdaq - DBTX). Press Release. 08/31/23; Press Release. Zevra Therapeutics to ...Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...The average twelve-month price prediction for Decibel Therapeutics is $8.45 with a high price target of $23.00 and a low price target of $2.00. Learn more on DBTX's analyst rating history. Do Wall Street analysts like Decibel Therapeutics more than its competitors?Nov 27, 2023 · 5 analysts have issued 1 year price targets for Decibel Therapeutics' shares. Their DBTX share price targets range from $2.00 to $23.00. On average, they predict the company's share price to reach $8.45 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View analysts price targets for DBTX or ...

Find the latest Financials data for Decibel Therapeutics, Inc. Common Stock (DBTX) at Nasdaq.com.Decibel Therapeutics, Inc. Common Stock (DBTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Oct 6, 2023 · https://www.decibeltx.com. Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company’s product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to ... Instagram:https://instagram. solid state batteries stockair conditioning companies stockbnd dividendshiba.inu news BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Based on analysts offering 12 month price targets for DBTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . nyse mpwbest stock screener app Decibel Therapeutics, Inc. Common Stock (DBTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.06-Sept-2023 ... Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC)'s sale to Nautic Partners for $10.50 in cash per share. If you are a Tabula Rasa shareholder, click ... penny stock options BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...Gainers Akouos, Inc. (NASDAQ:AKUS) shares jumped 89.4% to $13.27. Eli Lilly And Co (NYSE:LLY) agreed to acquire Akouos for a 78% premium over M...BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore ...